{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T06:28:10Z","timestamp":1793600890969,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jad.2026.121487","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:42:26Z","timestamp":1771918946000},"page":"121487","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Comparative effectiveness and safety of esketamine versus injectable racemic ketamine and oral antidepressants for major depressive disorder: A population-based target trial emulation"],"prefix":"10.1016","volume":"406","author":[{"given":"Ching-Hua Julie","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunzhe","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Cusin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin Sheng-Kai","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jad.2026.121487_bb0005","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/cpt.2640","article-title":"Population pharmacokinetics and pharmacodynamics of the therapeutic and adverse effects of ketamine in patients with treatment-refractory depression","volume":"112","author":"Abuhelwa","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"issue":"7354","key":"10.1016\/j.jad.2026.121487_bb0015","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature10130","article-title":"NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses","volume":"475","author":"Autry","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jad.2026.121487_bb2005","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jad.2020.09.071","article-title":"Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis","volume":"278","author":"Bahji","year":"2021","journal-title":"J. Affect. Disord."},{"issue":"6","key":"10.1016\/j.jad.2026.121487_bb0020","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1080\/14740338.2022.2047928","article-title":"Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis","volume":"21","author":"Bahji","year":"2022","journal-title":"Expert Opin. Drug Saf."},{"issue":"4","key":"10.1016\/j.jad.2026.121487_bb0025","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol. Psychiatry"},{"issue":"11","key":"10.1016\/j.jad.2026.121487_bb0030","doi-asserted-by":"crossref","first-page":"6704","DOI":"10.1038\/s41380-021-01093-2","article-title":"Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability","volume":"26","author":"Bonaventura","year":"2021","journal-title":"Mol. Psychiatry"},{"issue":"12","key":"10.1016\/j.jad.2026.121487_bb0035","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jama.2025.13350","article-title":"Transparent reporting of observational studies emulating a target trial-the TARGET statement","volume":"334","author":"Cashin","year":"2025","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.jad.2026.121487_bb0045","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1177\/0269881120922955","article-title":"Effects of subcutaneous esketamine on blood pressure and heart rate in treatment-resistant depression","volume":"34","author":"Del Sant","year":"2020","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.jad.2026.121487_bb0050","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1017\/S1461145712000545","article-title":"Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder","volume":"16","author":"Duncan","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2026.121487_bb0055","doi-asserted-by":"crossref","DOI":"10.1177\/20451253251394127","article-title":"Intravenous ketamine versus esketamine for depression: a systematic review and meta-analysis","volume":"15","author":"Elmosalamy","year":"2025","journal-title":"Ther. Adv. Psychopharmacol."},{"issue":"8","key":"10.1016\/j.jad.2026.121487_bb0065","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0006-3223(03)00231-2","article-title":"Diagnosis and definition of treatment-resistant depression","volume":"53","author":"Fava","year":"2003","journal-title":"Biol. Psychiatry"},{"issue":"18","key":"10.1016\/j.jad.2026.121487_bb0070","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1007\/s00213-014-3664-5","article-title":"Ketamine administration in depressive disorders: a systematic review and meta-analysis","volume":"231","author":"Fond","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"issue":"24","key":"10.1016\/j.jad.2026.121487_bb0075","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1001\/jama.2022.21383","article-title":"Target trial emulation: a framework for causal inference from observational data","volume":"328","author":"Hernan","year":"2022","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.jad.2026.121487_bb0080","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1001\/jamaophthalmol.2023.6089","article-title":"Epidermal growth factor receptor inhibitors for lung cancer and the risk of keratitis","volume":"142","author":"Huang","year":"2024","journal-title":"JAMA Ophthalmol."},{"issue":"1","key":"10.1016\/j.jad.2026.121487_bb0085","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.bja.2021.02.034","article-title":"Stereoselective ketamine effect on cardiac output: a population pharmacokinetic\/pharmacodynamic modelling study in healthy volunteers","volume":"127","author":"Kamp","year":"2021","journal-title":"Br. J. Anaesth."},{"issue":"3","key":"10.1016\/j.jad.2026.121487_bb0095","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00228-021-03216-8","article-title":"Use of ketamine and esketamine for depression: an overview of systematic reviews with meta-analyses","volume":"78","author":"Lima","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.jad.2026.121487_bb0100","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S2215-0366(17)30480-7","article-title":"Can we confidently use ketamine as a clinical treatment for depression?","volume":"5","author":"Loo","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2026.121487_bb0105","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1192\/bjp.2019.102","article-title":"Off-label use of ketamine for treatment-resistant depression in clinical practice: European perspective","volume":"215","author":"Lopez-Diaz","year":"2019","journal-title":"Br. J. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.jad.2026.121487_bb0110","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejphar.2013.06.028","article-title":"Comparison of the ex vivo receptor occupancy profile of ketamine to several NMDA receptor antagonists in mouse hippocampus","volume":"715","author":"Lord","year":"2013","journal-title":"Eur. J. Pharmacol."},{"issue":"10371","key":"10.1016\/j.jad.2026.121487_bb0115","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0140-6736(22)02080-3","article-title":"Novel and emerging treatments for major depression","volume":"401","author":"Marwaha","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jad.2026.121487_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2013.10.043","article-title":"Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach","volume":"156","author":"McIntyre","year":"2014","journal-title":"J. Affect. Disord."},{"issue":"5","key":"10.1016\/j.jad.2026.121487_bb0125","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation","volume":"178","author":"McIntyre","year":"2021","journal-title":"Am. J. Psychiatry"},{"issue":"10","key":"10.1016\/j.jad.2026.121487_bb0130","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.7326\/M22-1603","article-title":"The management of major depressive disorder: synopsis of the 2022 U.S. department of veterans affairs and U.S. department of defense clinical practice guideline","volume":"175","author":"McQuaid","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jad.2026.121487_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainresbull.2023.110724","article-title":"Electroacupuncture attenuates ketamine-induced neuronal injury in the locus coeruleus of rats through modulation of the CAMK II\/CREB pathway","volume":"202","author":"Miao","year":"2023","journal-title":"Brain Res. Bull."},{"issue":"2","key":"10.1016\/j.jad.2026.121487_bb0145","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jagp.2019.10.008","article-title":"Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-TRANSFORM-3","volume":"28","author":"Ochs-Ross","year":"2020","journal-title":"Am. J. Geriatr. Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2026.121487_bb0155","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19r12889","article-title":"Efficacy of esketamine augmentation in major depressive disorder: a meta-analysis","volume":"81","author":"Papakostas","year":"2020","journal-title":"J. Clin. Psychiatry"},{"issue":"9","key":"10.1016\/j.jad.2026.121487_bb0160","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1038\/s41380-020-0796-3","article-title":"Cell-type specific modulation of NMDA receptors triggers antidepressant actions","volume":"26","author":"Pothula","year":"2021","journal-title":"Mol. Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2026.121487_bb0165","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/da.22253","article-title":"Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression","volume":"31","author":"Price","year":"2014","journal-title":"Depress. Anxiety"},{"issue":"2","key":"10.1016\/j.jad.2026.121487_bb0170","doi-asserted-by":"crossref","first-page":"239","DOI":"10.7326\/M22-2056","article-title":"Nonpharmacologic and pharmacologic treatments of adults in the acute phase of major depressive disorder: a living clinical guideline from the American College of Physicians","volume":"176","author":"Qaseem","year":"2023","journal-title":"Ann. Intern. Med."},{"issue":"12","key":"10.1016\/j.jad.2026.121487_bb0175","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1001\/jamapsychiatry.2022.3352","article-title":"Efficacy and safety of ketamine vs electroconvulsive therapy among patients with major depressive episode: a systematic review and meta-analysis","volume":"79","author":"Rhee","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"11","key":"10.1016\/j.jad.2026.121487_bb0180","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2026.121487_bb0185","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jpsychires.2021.02.020","article-title":"Intranasal esketamine: from origins to future implications in treatment-resistant depression","volume":"137","author":"Sanders","year":"2021","journal-title":"J. Psychiatr. Res."},{"issue":"1","key":"10.1016\/j.jad.2026.121487_bb0190","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2215-0366(17)30272-9","article-title":"Side-effects associated with ketamine use in depression: a systematic review","volume":"5","author":"Short","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"10","key":"10.1016\/j.jad.2026.121487_bb0195","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1080\/14737175.2019.1640604","article-title":"Esketamine for treatment resistant depression","volume":"19","author":"Swainson","year":"2019","journal-title":"Expert Rev. Neurother."},{"issue":"10","key":"10.1016\/j.jad.2026.121487_bb0210","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1111\/all.16265","article-title":"Evaluation of dupilumab on the disease burden in children and adolescents with atopic dermatitis: a population-based cohort study","volume":"79","author":"Tsai","year":"2024","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.jad.2026.121487_bb0215","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.jaci.2024.07.019","article-title":"Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic dermatitis: a population-based cohort study","volume":"154","author":"Tsai","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.jad.2026.121487_bb0220","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/cpt.3478","article-title":"Ketamine and esketamine in clinical trials: FDA-approved and emerging indications, trial trends with putative mechanistic explanations","volume":"117","author":"Vekhova","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.jad.2026.121487_bb0225","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/jama.2017.10697","article-title":"Considerations on the off-label use of ketamine as a treatment for mood disorders","volume":"318","author":"Wilkinson","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jad.2026.121487_bb0230","doi-asserted-by":"crossref","DOI":"10.1177\/20451253241231264","article-title":"Patient-reported outcomes on sleep quality and circadian rhythm during treatment with intravenous ketamine for treatment-resistant depression","volume":"14","author":"Yan","year":"2024","journal-title":"Ther. Adv. Psychopharmacol."},{"issue":"9","key":"10.1016\/j.jad.2026.121487_bb0235","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.7326\/M24-0019","article-title":"Shifting trends in the indication of glucagon-like peptide-1 receptor agonist prescriptions: a nationwide analysis","volume":"177","author":"Yeo","year":"2024","journal-title":"Ann. Intern. Med."},{"issue":"3","key":"10.1016\/j.jad.2026.121487_bb0240","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.117.015198","article-title":"Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms","volume":"70","author":"Zanos","year":"2018","journal-title":"Pharmacol. Rev."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032726003381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032726003381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:45:35Z","timestamp":1793598335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032726003381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":41,"alternative-id":["S0165032726003381"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2026.121487","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative effectiveness and safety of esketamine versus injectable racemic ketamine and oral antidepressants for major depressive disorder: A population-based target trial emulation","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2026.121487","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"121487"}}